JP2017531043A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531043A5 JP2017531043A5 JP2017539524A JP2017539524A JP2017531043A5 JP 2017531043 A5 JP2017531043 A5 JP 2017531043A5 JP 2017539524 A JP2017539524 A JP 2017539524A JP 2017539524 A JP2017539524 A JP 2017539524A JP 2017531043 A5 JP2017531043 A5 JP 2017531043A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutically effective
- effective amount
- aed
- dosage form
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960003965 antiepileptics Drugs 0.000 claims description 18
- 239000002552 dosage form Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 7
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 6
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 4
- -1 levetiratum Chemical compound 0.000 claims description 4
- 229960003530 donepezil Drugs 0.000 claims description 3
- BMPDWHIDQYTSHX-AWEZNQCLSA-N (S)-MHD Chemical compound C1[C@H](O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-AWEZNQCLSA-N 0.000 claims description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 2
- XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 claims description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 2
- HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 claims description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 2
- 229960000571 acetazolamide Drugs 0.000 claims description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims description 2
- 229940049706 benzodiazepine Drugs 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000623 carbamazepine Drugs 0.000 claims description 2
- 229960004782 chlordiazepoxide Drugs 0.000 claims description 2
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims description 2
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001403 clobazam Drugs 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 229960004028 eslicarbazepine Drugs 0.000 claims description 2
- QIALRBLEEWJACW-INIZCTEOSA-N eslicarbazepine acetate Chemical compound CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 QIALRBLEEWJACW-INIZCTEOSA-N 0.000 claims description 2
- 229960003233 eslicarbazepine acetate Drugs 0.000 claims description 2
- 229960002767 ethosuximide Drugs 0.000 claims description 2
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims description 2
- 229960003533 ethotoin Drugs 0.000 claims description 2
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003472 felbamate Drugs 0.000 claims description 2
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 claims description 2
- 229960003980 galantamine Drugs 0.000 claims description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 2
- 229960002623 lacosamide Drugs 0.000 claims description 2
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims description 2
- 229960001848 lamotrigine Drugs 0.000 claims description 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 2
- 229960004640 memantine Drugs 0.000 claims description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 2
- 229960001816 oxcarbazepine Drugs 0.000 claims description 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims description 2
- 229960003396 phenacemide Drugs 0.000 claims description 2
- 229960002695 phenobarbital Drugs 0.000 claims description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002036 phenytoin Drugs 0.000 claims description 2
- 229960004136 rivastigmine Drugs 0.000 claims description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 2
- 229960002573 sultiame Drugs 0.000 claims description 2
- 229960004394 topiramate Drugs 0.000 claims description 2
- 229960004453 trimethadione Drugs 0.000 claims description 2
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 claims description 2
- 229940102566 valproate Drugs 0.000 claims description 2
- 229960005318 vigabatrin Drugs 0.000 claims description 2
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims description 2
- 229960002911 zonisamide Drugs 0.000 claims description 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims 3
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462065833P | 2014-10-20 | 2014-10-20 | |
| US62/065,833 | 2014-10-20 | ||
| PCT/US2015/056172 WO2016064711A1 (en) | 2014-10-20 | 2015-10-19 | A 19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020111574A Division JP2020152738A (ja) | 2014-10-20 | 2020-06-29 | 抗発作治療のためのａ１９−１４４、ａ２−７３およびある特定の抗コリンエステラーゼ阻害剤、組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017531043A JP2017531043A (ja) | 2017-10-19 |
| JP2017531043A5 true JP2017531043A5 (enExample) | 2018-11-22 |
Family
ID=55761357
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539524A Pending JP2017531043A (ja) | 2014-10-20 | 2015-10-19 | 抗発作治療のためのａ１９−１４４、ａ２−７３およびある特定の抗コリンエステラーゼ阻害剤、組成物および方法 |
| JP2020111574A Pending JP2020152738A (ja) | 2014-10-20 | 2020-06-29 | 抗発作治療のためのａ１９−１４４、ａ２−７３およびある特定の抗コリンエステラーゼ阻害剤、組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020111574A Pending JP2020152738A (ja) | 2014-10-20 | 2020-06-29 | 抗発作治療のためのａ１９−１４４、ａ２−７３およびある特定の抗コリンエステラーゼ阻害剤、組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US10441563B2 (enExample) |
| EP (1) | EP3209289A4 (enExample) |
| JP (2) | JP2017531043A (enExample) |
| CA (1) | CA2964520C (enExample) |
| WO (1) | WO2016064711A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018022848A1 (en) | 2016-07-27 | 2018-02-01 | Anavex Life Sciences Corp. | A2-73 as a therapeutic for insomnia, anxiety, and agitation |
| CN111712241B (zh) * | 2017-11-28 | 2024-02-13 | 阿纳韦克斯生命科学公司 | σ-1受体激动剂收缩期血压疗法 |
| CN112424600B9 (zh) | 2018-05-18 | 2024-07-02 | 阿纳韦克斯生命科学公司 | σ-1激动剂治疗的优化和受治疗者的筛选方法 |
| EP3883546A1 (en) | 2018-11-21 | 2021-09-29 | Rosemont Pharmaceuticals Ltd | Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability |
| US11194591B2 (en) | 2019-01-23 | 2021-12-07 | Salesforce.Com, Inc. | Scalable software resource loader |
| US10802944B2 (en) | 2019-01-23 | 2020-10-13 | Salesforce.Com, Inc. | Dynamically maintaining alarm thresholds for software application performance management |
| US10747551B2 (en) | 2019-01-23 | 2020-08-18 | Salesforce.Com, Inc. | Software application optimization |
| US10922062B2 (en) | 2019-04-15 | 2021-02-16 | Salesforce.Com, Inc. | Software application optimization |
| US10922095B2 (en) | 2019-04-15 | 2021-02-16 | Salesforce.Com, Inc. | Software application performance regression analysis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1002616B (el) * | 1996-02-21 | 1997-02-20 | Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης. | |
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| GR1005865B (el) | 2007-01-17 | 2008-04-07 | Anavex Life Sciences Corp. | Νεοι συνδετες των σιγμα υποδοχεων με αντι-αποπτωτικες και/η προ-αποπτωτικες ιδιοτητες επι των κυτταρικων βιοχημικων μηχανισμων, με νευρο-προστατευτικη, αντικαρκινικη, αντι-μεταστατικη και αντι- αντι-(χρονιο)φλεγμονικη δραση. |
| US20100297181A1 (en) | 2007-12-26 | 2010-11-25 | Eisai R&D Management Co., Ltd. | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ |
| GR1007686B (el) | 2011-07-08 | 2012-09-12 | Αλεξανδρος Δημητριου Βαμβακιδης | Συνθεση των (+) και (-) 1-(5,5-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης, (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης και (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν-μεθυλομεθυλαμινης |
| GR1008233B (el) * | 2013-03-28 | 2014-06-23 | Αλεξανδρος Δημητριου Βαμβακιδης | Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες |
-
2015
- 2015-10-19 US US15/571,877 patent/US10441563B2/en active Active
- 2015-10-19 EP EP15852696.2A patent/EP3209289A4/en active Pending
- 2015-10-19 JP JP2017539524A patent/JP2017531043A/ja active Pending
- 2015-10-19 CA CA2964520A patent/CA2964520C/en active Active
- 2015-10-19 WO PCT/US2015/056172 patent/WO2016064711A1/en not_active Ceased
-
2019
- 2019-10-14 US US16/601,323 patent/US10813907B2/en active Active
-
2020
- 2020-06-29 JP JP2020111574A patent/JP2020152738A/ja active Pending
- 2020-10-26 US US17/080,471 patent/US11690821B2/en active Active
-
2023
- 2023-05-18 US US18/320,159 patent/US20230301961A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531043A5 (enExample) | ||
| Rutgeerts | The limitations of corticosteroid therapy in Crohn’s disease | |
| JP2016518387A5 (enExample) | ||
| JP2018521042A5 (enExample) | ||
| JP2018506555A5 (enExample) | ||
| JP2019206593A5 (enExample) | ||
| JP2016540738A5 (enExample) | ||
| JP2019517469A5 (enExample) | ||
| RU2018108202A (ru) | Способы лечения синдрома леннокса-гасто с использованием фенфлурамина | |
| JP2016515628A5 (enExample) | ||
| AR049200A1 (es) | Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20 | |
| JP2014513089A5 (enExample) | ||
| JP2018503610A5 (enExample) | ||
| JP2017503014A5 (enExample) | ||
| JP2017507142A5 (enExample) | ||
| Muzina et al. | Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder | |
| JP2017512194A5 (enExample) | ||
| JP2013518914A5 (enExample) | ||
| JP2018524306A5 (enExample) | ||
| JP2014520856A5 (enExample) | ||
| JP2017524721A5 (enExample) | ||
| JP2017537927A5 (enExample) | ||
| JP2012526848A5 (enExample) | ||
| JP2014534229A5 (enExample) | ||
| JP2018506533A5 (enExample) |